Reported about 10 hours ago
Oppenheimer has reaffirmed its $95 price target and Outperform rating for DexCom, Inc. following Health and Human Services Secretary RFK Jr.'s announcement of a large-scale promotional campaign for wearables, particularly glucose monitoring devices. This initiative presents a promising opportunity for continuous glucose monitoring companies, with hints towards potential future coverage for over-the-counter CGMs. Recent advancements in CGM coverage for non-insulin Type 2 diabetes patients were also highlighted, including a DexCom-led trial set to conclude in late 2025 or early 2026.
Source: YAHOO